Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report published on Friday morning,Benzinga reports. They currently have a $320.00 target price on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the stock. Barclays upped their price objective […]
Needham & Company LLC reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report published on Friday morning,Benzinga reports. They currently have a $320.00 target price on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the stock. Barclays upped their price objective […]
